Skip to main content

Osteo Arthritis Shoulders

0
Pipeline Programs
4
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Exactech
ExactechFL - Gainesville
1 program
Exactech Shoulder Post Market Clinical Follow-up StudyN/A1 trial
Active Trials
NCT05603728Recruiting20,000Est. Dec 2031
Anika Therapeutics
Anika TherapeuticsMA - Bedford
1 program
MonoviscN/A1 trial
Active Trials
NCT04204265Completed25Est. Mar 2021
Innovation Pharmaceuticals
1 program
reverse total shoulder arthroplastyN/A1 trial
Active Trials
NCT03617107Unknown150Est. Dec 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Anika TherapeuticsMonovisc
Innovation Pharmaceuticalsreverse total shoulder arthroplasty
ExactechExactech Shoulder Post Market Clinical Follow-up Study

Clinical Trials (3)

Total enrollment: 20,175 patients across 3 trials

MONOVISC for Shoulder Joint Pain Relief Due to Osteoarthritis

Start: Dec 2019Est. completion: Mar 202125 patients
N/ACompleted
NCT03617107Innovation Pharmaceuticalsreverse total shoulder arthroplasty

Reverse Total Shoulder Arthroplasty: A Data Analysis on Patients Undergoing Reverse Total Shoulder Arthroplasty

Start: Dec 2017Est. completion: Dec 2020150 patients
N/AUnknown
NCT05603728ExactechExactech Shoulder Post Market Clinical Follow-up Study

Exactech Shoulder Post Market Clinical Follow-up Study

Start: Jul 2007Est. completion: Dec 203120,000 patients
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 20,175 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.